Lataa...
Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone
Imatinib, the frontline tyrosine kinase inhibitor (TKI), has revolutionised the management of chronic myeloid leukaemia (CML). Severe hepatotoxicity, although uncommon, can occur with this drug. This tends to subside with dose reduction or cessation, but can recur with reintroduction of the drug. Re...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMJ Publishing Group
2011
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3062883/ https://ncbi.nlm.nih.gov/pubmed/22707550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr.11.2010.3516 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|